British Patient Capital

Portfolio Companies 2026 for British Patient Capital: investors, rounds, and co-investor patterns from StartupFundraising.com research, updated for 2026.

British Patient Capital accounts for 14 tracked companies with verified cap-table data, 14 of which disclose round sizes totalling $2.1B. The median disclosed raise is $120M, and the largest is Quell Therapeutics at $344M, ahead of Tokamak Energy ($335M) and Quantum Motion ($251M).

The names that recur most often on these portfolio cap tables are British Patient Capital (15 companies), Sofinnova Partners (3 companies), Syncona (2 companies), UCL Technology Fund (2 companies), British Business Bank (2 companies), Oxford Science Enterprises (2 companies). By latest disclosed round, the market skews Series B (4), Series C (4), Series A (4), Series D (1).

Best funded British Patient Capital companies

  1. Quell Therapeutics — $344M (latest: Series B)
  2. Tokamak Energy — $335M
  3. Quantum Motion — $251M (latest: Series C)
  4. Ultraleap — $242M (latest: Series D)
  5. Nuclera — $145M (latest: Series C)
  6. Grey Wolf Therapeutics — $131M (latest: Series B)
  7. Perspectum — $120M (latest: Series C)
  8. Myricx Bio — $114M (latest: Series A)
  9. Purespring Therapeutics — $105M (latest: Series B)
  10. Microbiotica — $73M (latest: Series B)
  11. Maxion Therapeutics — $72M (latest: Series A)
  12. Tenpoint Therapeutics — $70M (latest: Series A)
  13. Paragraf — $55M (latest: Series C)
  14. Curve Therapeutics — $51M (latest: Series A)

British Patient Capital — related firms and companies (56)

British Patient Capital alternatives · All research reports